Personalized Medicine: A Case Study of Academic-Industry Collaboration
Date & Time
In discussing strategies for academic?industry alliances, Patrick Groody, a Divisional Vice President with Abbott Molecular referenced this quote from Steven Covey during the August 8 Exploring Ethics program. Groody was joined by Richard Schwab, director for the UC San Diego Moores Cancer Center Biorepository, as a panelist for this second program in the Ethics Center's 2012 Summer Series on Meeting the Challenge of Conflicts of Interest. For this program titled Personalized Medicine: A Case Study of Academic-Industry Collaboration, Groody and Schwab repeatedly emphasized the compelling need for new and improved diagnostics and therapeutics to better serve patients. With this end in mind, the evening's discussion examined the arguments for academic-industry partnerships, how those partnerships might be best constructed, and some of the challenges that need to be addressed.
This program was made possible in part by support from:
Please note that this program was held at:
- Sanford Consortium for Regenerative Medicine
- 2880 Torrey Pines Scenic Drive
- La Jolla, California
This was the second of three programs in the Ethics Center's Summer Series 2012, titled:
Meeting the Challenge of Conflicts of Interest: Academic-Industry Collaborations.
This series seeks to find answers to two central questions:
- What are the challenges raised by conflicts of interest when industry enters into collaborations with academic partners?
- What existing or new mechanisms might mitigate or eliminate the real or perceived ways in which such collaborations compromise the integrity of science?
Pat Groody is the Divisional Vice President, Research & Development, Abbott Molecular. Pat started his career in 1986 as a Research Scientist at Amoco Corporation in Naperville, IL. From 1987-1992 he was Technical Support Manager at GENE-TRAK Systems in Framingham, MA. Pat joined Abbott in 1992 as Manager, Technical Support in the Abbott Diagnostics Division. From 1999-2001 he was Director of New Product Development for Abbott in Wiesbaden Germany. From 2001-2002 he was Sr. Director of Area Manufacturing Operations, also in Wiesbaden. In 2002 he returned to Abbot Diagnostics in Illinois and became Director of Research and Development. He became Sr. Director of Manufacturing and Operations from 2003-2005 in Downers Grove, IL. From 2005-2006 he became Sr. Director Operations for Abbott Molecular in Des Plaines, IL. He was promoted to a Divisional Vice President Quality and Operations for Abbott Molecular in 2006-2009 and became Divisional Vice President and General Manager, IBIS at Abbott Molecular in Des Plaines, IL from 2009-2011. Pat is currently the Divisional Vice President Research & Development, responsible for all assay and systems research and developments projects for Abbott Molecular, Des Plaines, IL. Pat has a BS in Chemistry from University of Connecticut an MS in Organic Chemistry and Ph.D. from Northwestern University.
UC San Diego
Dr. Schwab's research focuses on biomarkers to diagnose and refine the treatment of cancer. In support of biomarker studies, Dr Schwab directs the UCSD Moores Cancer Center biorepository which prospectively collects de-identified blood, urine and tumor specimens. This biorepository consents its donors for use of their specimens by for-profit end users. Over the last 6 years a large number of pharmaceutical and biotechnology companies have used these specimens to study new cancer biomarkers and drugs. Dr. Schwab also has direct experience with the FDA both with his own investigator IND and as a consultant to the pharmaceutical industry, specifically supporting an IND submission in metastatic breast cancer. Lastly he was a co-founder of Wintherix LLC, a startup biotechnology company focused on drug discovery in the Wnt pathway.